Trial Profile
A Placebo Controlled, Randomized, Double-Blind, Fixed-dose, Multicenter, Phase IIb Study to Investigate the Efficacy and Tolerability of BAY 58-2667 (50 ug/h, 100 ug/h, 150 ug/h) Given Intravenously to Subjects With Acute Decompensated Chronic Congestive Heart FailUre (ADHF) Within 12 Hours After Hospital Admission (Pulmonary Artery Catheter eg, Swan-Ganz Not Required).
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 10 Jan 2022
Price :
$35
*
At a glance
- Drugs Cinaciguat (Primary)
- Indications Decompensated heart failure
- Focus Therapeutic Use
- Acronyms COMPOSE-EARLY
- Sponsors Bayer; Bayer HealthCare
- 12 Jul 2019 This trial has been completed in France, according to European Clinical Trials Database.
- 25 Feb 2011 Planned end date changed from 1 Sep 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
- 25 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.